Implementing Evidence-Based Strategies to Improve Pediatric Oncology Infection Management Blinatumomab has rapidly emerged as a cornerstone in the treatment of B-cell ALL (B-ALL) across age and risk ...

Blinatumomab has rapidly emerged as a cornerstone in the treatment of B-cell ALL (B-ALL) across age and risk groups. Initially approved for minimal residual disease (MRD)–positive adult B-ALL in 2018, ...

Despite failing to achieve MRD-negativity after induction, patients with Ph+ acute lymphoblastic leukemia treated with ...

That bond was created during a special day in Las Vegas. Golden Circle of Champions provided Western outfits for the children, and Michael suited up with a signed cowboy hat, jeans and a nice shirt ...

The following is a summary of “Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ...

In 2024, a series of case reports in which bispecific antibodies approved for oncology indications (blinatumomab, teclistamab) were used to treat patients with autoimmune diseases (such as ...

and Blincyto (blinatumomab) which are licensed elsewhere but in late-stage development in China. BeiGene and Amgen say they will share the profits and losses from the drugs. Two of those drugs ...

Those problems mean that so far only one T-cell engager has reached the market – Amgen’s Blincyto (blinatumomab) for leukaemia – although many others are coming through development.

Это поможет нам в нужный момент заменить пакет с blinatumomab. Если возникла проблема с помпой, инфузионной системой или имплантируемым портом, сразу же звоните по телефону 202-639-2000 .